Dina E Bali1, Mohamed A Osman1, Gamal M El Maghraby2. 1. Department of Pharmaceutical Technology, College of Pharmacy, University of Tanta, Tanta, Egypt. 2. Department of Pharmaceutical Technology, College of Pharmacy, University of Tanta, Tanta, Egypt. gmmelmag@yahoo.com.
Abstract
BACKGROUND AND OBJECTIVES: Clopidogrel is an antiplatelet and antithrombotic prodrug. It has poor oral bioavailability due to poor dissolution and possible premature degradation in the intestine. Accordingly, the objective of this study was to enhance clopidogrel dissolution rate and to reduce its premature degradation in rabbit intestine. METHODS: Solid dispersion (SD) systems of clopidogrel with gelucire 50/13 and/or cremophor RH40 were prepared using fusion technique. The SD systems were characterized with respect to drug dissolution. The characterization included thermal analysis and infrared investigations. The stability of clopidogrel in the fluid extracted from small intestinal and colonic mucosal surfaces was monitored both in absence and presence of cremophor or gelucire. RESULTS: SD formation enhanced drug dissolution with the enhancement increasing at higher concentrations of either cremophor or gelucire. The ternary SD of clopidogrel with cremophor and gelucire reflected synergism between them. This synergism was manifested by enhanced dissolution efficiency of drug to reach 85 % at pH 6.8 and 89 % at pH 7.4 compared to unprocessed drug which liberated 16.2 and 15.2 % at the same pH values, respectively. Enhanced dissolution from SD was mainly due to micellar solubilization for cremophor and was due to change in the crystalline nature of drug with a contribution to self-emulsification in case of gelucire. Clopidogrel showed premature degradation in the intestinal fluid. Cremophor RH 40 reduced this degradation but gelucire failed in this respect. CONCLUSION: The study introduced SD system for enhanced dissolution rate of clopidogrel with a potential of reduced premature degradation in the intestine.
BACKGROUND AND OBJECTIVES:Clopidogrel is an antiplatelet and antithrombotic prodrug. It has poor oral bioavailability due to poor dissolution and possible premature degradation in the intestine. Accordingly, the objective of this study was to enhance clopidogrel dissolution rate and to reduce its premature degradation in rabbit intestine. METHODS: Solid dispersion (SD) systems of clopidogrel with gelucire 50/13 and/or cremophor RH40 were prepared using fusion technique. The SD systems were characterized with respect to drug dissolution. The characterization included thermal analysis and infrared investigations. The stability of clopidogrel in the fluid extracted from small intestinal and colonic mucosal surfaces was monitored both in absence and presence of cremophor or gelucire. RESULTS:SD formation enhanced drug dissolution with the enhancement increasing at higher concentrations of either cremophor or gelucire. The ternary SD of clopidogrel with cremophor and gelucire reflected synergism between them. This synergism was manifested by enhanced dissolution efficiency of drug to reach 85 % at pH 6.8 and 89 % at pH 7.4 compared to unprocessed drug which liberated 16.2 and 15.2 % at the same pH values, respectively. Enhanced dissolution from SD was mainly due to micellar solubilization for cremophor and was due to change in the crystalline nature of drug with a contribution to self-emulsification in case of gelucire. Clopidogrel showed premature degradation in the intestinal fluid. Cremophor RH 40 reduced this degradation but gelucire failed in this respect. CONCLUSION: The study introduced SD system for enhanced dissolution rate of clopidogrel with a potential of reduced premature degradation in the intestine.
Authors: Heleen J Bouman; Edgar Schömig; Jochem W van Werkum; Janna Velder; Christian M Hackeng; Christoph Hirschhäuser; Christopher Waldmann; Hans-Günther Schmalz; Jurriën M ten Berg; Dirk Taubert Journal: Nat Med Date: 2010-12-19 Impact factor: 53.440
Authors: A S Borde; E M Karlsson; K Andersson; K Björhall; H Lennernäs; B Abrahamsson Journal: Eur J Pharm Biopharm Date: 2011-12-04 Impact factor: 5.571
Authors: Marissa A Schiel; Scheri-lyn Green; Wilhelmina I Davis; Paresh C Sanghani; William F Bosron; Sonal P Sanghani Journal: J Pharmacol Exp Ther Date: 2007-07-17 Impact factor: 4.030
Authors: Richard H Parrish; Lisa D Ashworth; Raimar Löbenberg; Sandra Benavides; Jeffrey J Cies; Robert B MacArthur Journal: Pharmaceutics Date: 2022-05-10 Impact factor: 6.525
Authors: Jie Li; Zhijian Hong; Hong Liu; Jihong Zhou; Lei Cui; Siming Yuan; Xianghua Chu; Pan Yu Journal: Front Pharmacol Date: 2016-04-22 Impact factor: 5.810